Trump Signs Executive Order to Loosen Restrictions on Psychedelic Drugs for Mental Health Research
The president's order aims to accelerate research into compounds like psilocybin and ibogaine for treating severe depression and PTSD.
Trump Signs Executive Order to Loosen Restrictions on Psychedelic Drugs for Mental Health Research
The president's order aims to accelerate research into compounds like psilocybin and ibogaine for treating severe depression and PTSD.
This article covers developments reported by NYT. Related topics: psychedelics, mental health, Trump, executive order, FDA, research.
Trump Signs Executive Order to Loosen Restrictions on Psychedelic Drugs for Mental Health Research. The president's order aims to accelerate research into compounds like psilocybin and ibogaine for treating severe depression and PTSD. Sources close to the matter have confirmed the key details of this developing story. As events continue to unfold, further information is expected to emerge in the coming hours and days. Observers note that this development carries significant implications for the broader context in which these events are taking place. The situation is being closely monitored by officials, analysts, and affected parties, all of whom are assessing the potential consequences and next steps.
Reporting by NYT. Additional details may be updated as they become available.
Originally reported by NYT.